Metformin: Is it Still the First Line in Type 2 Diabetes Management Algorithm?

Area of Science:

• Endocrinology and Metabolism
• Pharmacology
• Public Health

Background:

• Type 2 diabetes mellitus (T2DM) affects 1 in 11 adults globally, causing significant morbidity, mortality, and healthcare costs.
• Metformin has been the standard first-line oral therapy for T2DM for decades, offering glycemic benefits and a favorable safety profile.
• Recent advancements in diabetes pharmacotherapy and cardiovascular outcome trials have complicated treatment algorithms.

Purpose of the Study:

• To review the historical context and origins of metformin.
• To evaluate metformin's current role in T2DM management, focusing on clinical efficacy and safety.
• To discuss metformin's position within contemporary T2DM treatment guidelines amidst evolving evidence.

Main Methods:

• Narrative review of existing literature.
• Analysis of landmark studies and recent large-scale cardiovascular safety trials.
• Examination of current clinical guidelines and treatment algorithms for T2DM.

Main Results:

• Metformin demonstrates a well-established glycaemic benefit with a low risk of hypoglycemia.
• Evidence suggests potential protective effects of metformin on organs affected by diabetes complications.
• Newer agents and cardiovascular risk stratification are influencing first-line treatment choices, challenging metformin's traditional role.

Conclusions:

• Metformin's efficacy, safety, and historical significance continue to support its use in T2DM management.
• Treatment decisions are increasingly individualized, balancing glycemic control, cardiovascular risk, and patient-specific factors.
• The evolving landscape necessitates a nuanced understanding of metformin's place in modern T2DM therapy.